Treatment for metastatic nasopharyngeal carcinoma

Bensouda, Y.; Kaikani, Wafaa; Ahbeddou, N.; Rahhali, R.; Jabri, Mouna; Mrabti, Hind; Boussen, H; Errihani, Hassan

doi:10.1016/j.anorl.2010.10.003

Cited by 134 publications

(129 citation statements)

References 43 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…After primary treatment with radiotherapy or chemoradiotherapy, more than one third of patients will relapse with locoregional recurrence and distant metastases (2). Most patients who recur or develop distant metastases are only amenable to palliative chemotherapy or radiotherapy and overall survival after recurrence is poor with reported median survival ranging from 7.2 to 22 months (3)(4)(5). Epstein-Barr virus (EBV) is present in virtually all poorly differentiated and undifferentiated nonkeratinizing NPC (WHO type II and III).…”

Section: Introductionmentioning

confidence: 99%

Effective Treatment of Metastatic Forms of Epstein-Barr Virus–Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy

et al. 2012

View full text Add to dashboard Cite

Nasopharyngeal carcinoma (NPC) is endemic in China and Southeast Asia where it is tightly associated with infections by Epstein-Barr virus (EBV). The role of tumor-associated viral antigens in NPC renders it an appealing candidate for cellular immunotherapy. In earlier preclinical studies, a novel adenoviral vector-based vaccine termed AdE1-LMPpoly has been generated that encodes EBV nuclear antigen-1 (EBNA1) fused to multiple CD8 þ T-cell epitopes from the EBV latent membrane proteins, LMP1 and LMP2. Here, we report the findings of a formal clinical assessment of AdE1-LMPpoly as an immunotherapeutic tool for EBV-associated recurrent and metastatic NPC. From a total of 24 patients with NPC, EBV-specific T cells were successfully expanded from 16 patients with NPC (72.7%), whereas six patients with NPC (27.3%) showed minimal or no expansion of virus-specific T cells. Transient increase in the frequencies of LMP1&2-and EBNA1-specific T-cell responses was observed after adoptive transfer to be associated with grade I flu-like symptoms and malaise. The time to progression in these patients ranged from 38 to 420 days with a mean time to progression of 136 days. Compared with patients who did not receive T cells, the median overall survival increased from 220 to 523 days. Taken together, our findings show that adoptive immunotherapy with AdE1-LMPpoly vaccine is safe and well tolerated and may offer clinical benefit to patients with NPC. Cancer Res; 72(5); 1116-25. Ó2012 AACR.

show abstract

Section: Introductionmentioning

confidence: 99%

Effective Treatment of Metastatic Forms of Epstein-Barr Virus–Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy

et al. 2012

View full text Add to dashboard Cite

show abstract

“…For cases that have spread beyond the nasopharynx (i.e., cancer stages II, III, IVA and IVB), the addition of chemotherapy is common. Typically, platinum based agents, including cisplatin or carboplatin are used to treat NPC alongside fluorouracil (3). However, these medications also harm normal cells, causing side effects that include a decrease in white blood cells, anemia, kidney toxicity and nausea.…”

Section: Introductionmentioning

confidence: 99%

Celastrol-induced apoptosis in human nasopharyngeal carcinoma is associated with the activation of the death receptor and the mitochondrial pathway

et al. 2017

View full text Add to dashboard Cite

Abstract. Nasopharyngeal carcinoma (NPC) is a cancer that arises from the epithelium of the nasopharynx. Celastrol is a triterpene from traditional Chinese medicine, which demonstrates anti-proliferative activity in several cancer cell lines. However, the effect of celastrol on human NPC and the underlying mechanisms are not yet elucidated. The present study investigated whether celastrol induced apoptosis in human NPC cells, and the underlying molecular mechanisms were explored. Celastrol decreased the viability of HONE-1 and NPC-039 cells in a dose-dependent manner, and induced G1 and G2/M phase cell cycle arrest. The level of cleaved caspases-3, -8, and -9 and poly (ADP-ribose) polymerase 1 increased in cells treated with celastrol. There was an increase in active Bcl-2-like 11 isoform S, Bcl-2-associated X, Bcl-2 antagonist/killer and truncated BH3-interacting death antagonist, and the levels of the anti-apoptotic Bcl-2 and Bcl-2-like 1 decreased. Celastrol induced an increase in Fas, Fas-associated via death domain, TNF receptor superfamily members (TNRSF) 1A and 10B, and TNFRSF1A associated via death domain, and induced a dose-dependent reduction in mitochondrial membrane potential. Celastrol inhibited activation of mitogen-activated protein kinase (MAPK) 1/3 and 14, and induced MAPK 8/9 activation. The results indicated that celastrol induced apoptosis through the death receptor and the mitochondrial pathway in human NPC cells, and is a promising candidate in the development of drugs against NPC. IntroductionNasopharyngeal carcinoma (NPC) is a cancer that arises from the epithelium of nasopharynx. This cancer is uncommon in Europe and America, and its incidence is higher in Africa and Southeast Asia (1). Its unique epidemiology, pathogenesis and association with the Epstein-Barr virus make it distinct from other types of head and neck cancer. Although NPC is reported to respond well to radiation therapy, chemotherapy also has a function in the current treatment protocol (2). For cases that have spread beyond the nasopharynx (i.e., cancer stages II, III, IVA and IVB), the addition of chemotherapy is common. Typically, platinum based agents, including cisplatin or carboplatin are used to treat NPC alongside fluorouracil (3). However, these medications also harm normal cells, causing side effects that include a decrease in white blood cells, anemia, kidney toxicity and nausea.Apoptosis, the process of programmed cell death, is a crucial self-defense mechanism for the human body to counteract cancerous cells. A number of existing chemotherapeutic agents aim to initiate the apoptosis cascade for an anti-tumor effect (4,5). However, as the disease progresses, certain cancer cell populations become resistant to chemotherapeutic agents and the efficacy of chemotherapy gradually deteriorates. Therefore, developing novel chemotherapeutic agents against NPC is crucial.Tripterygium wilfordii, also known as thunder god vine, is an herb traditionally used in Asia to treat various diseases, including tissue inflammation...

show abstract

“…Bone is the most frequent involved organ by metastasis among patients with NPC, with an estimated incidence rate of 54%-80% in that group [9][10][11][12]. The frequently involved metastatic sites included spine, pelvis, and ribs, and the prognosis of patients with NPC and bone metastasis varied, with occasional long-term survivors [13][14][15].…”

Section: Introductionmentioning

confidence: 99%

M1 Stage Subdivision and Treatment Outcome of Patients With Bone-Only Metastasis of Nasopharyngeal Carcinoma

et al. 2015

View full text Add to dashboard Cite

Background. The current M1 stage in nasopharyngeal carcinoma (NPC) does not differentiate patients based on metastatic site and number of metastases. This study aims to subdivide the M1 stage of NPC patients with bone-only metastases and to identify the patients who may benefit from combined chemoradiotherapy (CRT). Methods. Between 1998 and 2007, 312 patients diagnosed with bone-only metastasis at Sun Yat-sen University Cancer Center were enrolled.Various possible subdivisions of M1 stage were considered, including by the time order of metastasis (synchronous vs. metachronous), involvement of specific bone metastatic site, the number of metastatic sites, and the number of metastases. The correlation of the subdivisions of M1 stage with overall survival (OS) was determined by Cox regression. Results. The median OS was 23.4 months. Patients with more than three metastatic sites had significantly poorer OS than patients with three or fewer metastatic sites (16.2 vs. 32.4

show abstract

Treatment for metastatic nasopharyngeal carcinoma

Cited by 134 publications

References 43 publications

Effective Treatment of Metastatic Forms of Epstein-Barr Virus–Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy

Effective Treatment of Metastatic Forms of Epstein-Barr Virus–Associated Nasopharyngeal Carcinoma with a Novel Adenovirus-Based Adoptive Immunotherapy

Celastrol-induced apoptosis in human nasopharyngeal carcinoma is associated with the activation of the death receptor and the mitochondrial pathway

M1 Stage Subdivision and Treatment Outcome of Patients With Bone-Only Metastasis of Nasopharyngeal Carcinoma

Contact Info

Product

Resources

About